Safety and efficacy of HAIC or lenvatinib combined with sintilimab as neoadjuvant therapy for high recurrence risk resectable stage IB solitary hepatocellular carcinoma: A prospective, randomized, two-cohort, exploratory phase II clinical study.

Authors: Yunlong Cui, Chen Liu, Qiang Wu, Han Mu, Ge Yu, Dongming Liu, Xu Bao, Feng Fang, Wei Zhang, Huikai Li, Ping Chen, Hongyuan Zhou, Xiaomeng Liu, Lu Chen, Tianqiang Song

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e16288

Source: Full article

---

Abstract

e16288